A Phase 2, Multiple-Cohort, Open-Label, International Study of Talazoparib Monotherapy and Talazoparib Plus Temozolomide in Women With Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Talazoparib (Primary) ; Temozolomide (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Medivation; Pfizer
- 20 Dec 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 20 Jul 2016 New trial record